TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Measurement of AESI
Endpoint domain: Adverse events/effects
Primary endpoint: Intervention Satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mobilisation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital acquired infections
Endpoint domain: Adverse events/effects
Primary endpoint: Bioelectrical activity of quadriceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in anxiety symptoms (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in anxiety symptoms (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Histologic Fibrosis Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of participants with Treatment Emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: PK parameters for ASC10, GLC01-700 (molnupiravir) and ASC10-A in plasma as AUC0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Conscious Awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Optimal biological dose (OBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pancreatic beta cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: pancreatic beta cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Development or progression of acute delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PADIS assessment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting glucose value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence and severity of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Clinical Remission at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subscapularis repair integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Mindfulness during treatment phase
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quality of life during treatment phase
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Clinical Improvement of Depression during treatment phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Diet Adherence Assessment Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavioral Speech Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mood and behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parkinson's Disease (PD) symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of psilocybin therapy for depression and anxiety in people with PD
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Satisfaction of psilocybin therapy for depression and anxiety in people with PD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Exhaled Breath Carbon Monoxide (CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of Life (IQOL) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Global Impression of Improvement (PGI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maternal Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and type of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants who activate MyChart Proxy Access
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Difference in Maximal Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial-Venous (A-V) O2 difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment MRI assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in tinnitus severity and annoyance on the tinnitus hearing survey (THS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the Sound Tolerance Questionnaire ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change on the Tinnitus Functional Index (TFI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change on the Tinnitus Primary Function Questionnaire (TPFQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in tinnitus and hyperacusis ratings on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weekly MME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity and reliability of the Hand10 questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone turnover marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone formation marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of deaths among participants
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients weaned from parenteral analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief-Pain Inventory (BPI)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Severity of Symptoms between Pfizer and Moderna
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Symptoms between Homologous vs Heterologous Regiments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUC∞) of Brensocatib in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac flow measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement Percentage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weekly Achievement Percentage
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Study-Drug Related Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Central macular thickness after 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cystoid macular edema (CME) after 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of the tibial nerve with ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentration of chlordiazepoxide and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year risk of recurrent stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reoperation for any reason
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in dry eye symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Receiving Injection 2 at the Week 2 Visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Responders for Weekly Opioid Use Over Weeks 10 to 38
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Days Opioids were Used over Weeks 10 to 38
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oral pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva Production unstimulated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva Production stimulated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18-months progression-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Primary Implant Stability Quotient (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of CKD-828, D064+D701
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-828, D064+D701
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin fragment F1+2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Graft failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: ACL-Return to sport after injury (ACL-RSI)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Extent of adherence to antiretroviral treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: restoration of dentition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity and specificity of early detection of cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tissue of origin (TOO) accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in resting anorectal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement of Immunoglobulin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of cortisol hormone rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol hormone concentration using hair cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Seroprevalence of pre-existing antibodies to AAV9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in Worst Itch Numeric Rating Scale (WI-NRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects experiencing a device and/or procedure-related serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from documented AF/AFL/AT episodes of greater than 30 seconds duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Develop Grade 3 or Higher drug-related Pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Consent Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Study Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tandem Stance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol urges
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Berg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Synovitis Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic Literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: undetectable HIV-1 plasma viral load at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in restricted repetitive behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in social communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in emotion disregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline hemarthrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interproximal clinical attachment level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular (CV) mortality
Endpoint domain: Mortality/survival
Primary endpoint: Nonfatal MI, stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRD negativity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Response rate (CR + mCR + PR + HI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematologic outcomes
Primary endpoint: Resting pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated haemoglobin (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment emergent, treatment related, and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from Baseline in clinical laboratory evaluations following study drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline in vital signs following study drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness of sensory integration therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference of mean CCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference of mean dP/dt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference of mean SVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference of mean CPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference of mean Ea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative incidence and grade of graft-versus-host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of GVHD-free, relapse-free survival (GRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline parent Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline parent health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline child body mass index percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropathic pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of TEAEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Osvestry Disability index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability of CAR T-cells
Endpoint domain: Adverse events/effects
Primary endpoint: Pressure time-product (PTP) per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Esophageal pressure swings (ΔPes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Monocular Visual Performance (LogMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in pain and swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of enrollment in cervical cancer clinical study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants remaining in clinical trial until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Level of pain after treatment based on Wong-Baker Faces (WBF) pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of dental anxiety after treatment using Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: high nurses' system usability perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 30sec sit to stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm curl field test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of MCAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of recovery-15 score at 48 hrs postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adherence to secondary cardiovascular prevention recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time-to-sustained-resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood LDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in FACT-B+4 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in modified Rankin Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroduodenal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of monocyte soluble activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of positive and negative cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in torques at the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Differences in forces at the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Durable Clinicohematologic Response (DCHR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Breathlessness intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gingival thickness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized tissue width improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Landing Error Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Y- Balance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Movement Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of coffee compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal carotid artery angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Internal carotid artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Strength and Difficulty Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participants acceptance and experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pemberton Happiness Index (PHI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of clinical periodontal indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change of pancreatic T1 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t (area under the curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital caseload
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Diagnostic accuracy of AI4CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of AI4CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of AI4CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypotension during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of hypotension during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Withdrawals due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Changes in Vital Signs Data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ALC Reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intergenerational co-parenting relationship
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Center of Pressure (COP) balance control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking speed over obstacle course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal excitability via Soleus H-reflex testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes